Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 14 h ago

CRESCENT BIOPHARMA, INC.: Venrock Healthcare Capital Partners III, L.P. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Venrock Healthcare Capital Partners III, L.P. amended its Schedule 13G stake filing for Crescent Biopharma, Inc., disclosing the change to the SEC under accession number 0001738048-26-000090. The filing updates the venture firm's previously reported beneficial ownership position in the biopharma company. Schedule 13G amendments are typically filed by passive investors when their holdings cross or adjust relative to the 5% reporting threshold. The specific revised share count and ownership percentage were not detailed in the headline disclosure. Investors will watch for the full filing text to confirm whether Venrock's position increased or decreased and by how much.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Venrock Healthcare Capital Partners III, L.P., Crescent Biopharma, Inc.